Delving into the Latest Updates on Siponimod Fumaric Acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

siponimod, Siponimod fumarate, BAF-312

+ [6]

Target

S1PR1 x S1PR5

Action

modulators

Mechanism

S1PR1 modulators(Sphingosine 1-phosphate receptor Edg-1 modulators), S1PR5 modulators(Sphingosine 1-phosphate receptor Edg-8 modulators)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesOther Diseases

Active Indication

Multiple Sclerosis, Secondary ProgressiveMultiple SclerosisAlzheimer Disease+ [1]

Inactive Indication

Cerebral HemorrhageDermatomyositisHemorrhagic stroke+ [4]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Pharmaceuticals Corp.

Novartis Pharma KKNovartis Europharm Ltd.

+ [4]

Inactive Organization

Novartis Pharma AG

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (26 Mar 2019),

Multiple Sclerosis

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC33H39F3N2O7

InChIKeyGDOJWCQYEGMSSF-FLNKEUCSSA-N

CAS Registry1234627-85-0

Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.

Start Date01 Jul 2025

Sponsor / Collaborator

St. Joseph's Medical Center, Inc.

[+5]

CTR20232992

/ CompletedNot Applicable

西尼莫德片的人体生物等效性研究

[Translation] Study on the bioequivalence of siponimod tablets in healthy volunteers

研究空腹/餐后状态下单次口服受试制剂西尼莫德片与参比制剂西尼莫德片（万立能®）在健康成年受试者体内的药代动力学，评价空腹/餐后状态下口服两种制剂的生物等效性和安全性。

[Translation]

The pharmacokinetics of a single oral dose of the test preparation Siponimod tablets and the reference preparation Siponimod tablets (Vanlin®) in healthy adult subjects were studied in the fasting/postprandial state, and the bioequivalence and safety of the two preparations were evaluated in the fasting/postprandial state.

Start Date23 Sep 2023

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

CTR20230278

/ CompletedPhase 4

一项在中国复发型多发性硬化患者中评价BAF312的有效性和安全性的回顾性、多中心真实世界研究。

[Translation] A retrospective, multicenter, real-world study evaluating the efficacy and safety of BAF312 in Chinese patients with relapsing multiple sclerosis.

1.在中国真实世界人群中，基于年复发率描述BAF312在复发型多发性硬化(RMS)患者中的有效性。 2.描述开始BAF312治疗后12个月时保持无复发的患者比例。 3.在中国真实世界人群中描述BAF312在RMS患者中的安全性特征。 4.描述开始BAF312治疗后12个月时无MRI活动性的患者比例。

[Translation]

1. Describe the efficacy of BAF312 in patients with relapsing multiple sclerosis (RMS) based on annualized relapse rate in a real-world Chinese population. 2. Describe the proportion of patients who remain relapse-free at 12 months after starting BAF312 treatment. 3. Describe the safety profile of BAF312 in patients with RMS in a real-world Chinese population. 4. Describe the proportion of patients with no MRI activity at 12 months after starting BAF312 treatment.

Start Date23 Apr 2023

Sponsor / Collaborator

Novartis Farmacéutica SA

[+3]

100 Clinical Results associated with Siponimod Fumaric Acid

Login to view more data

100 Translational Medicine associated with Siponimod Fumaric Acid

Login to view more data

100 Patents (Medical) associated with Siponimod Fumaric Acid

Login to view more data

352

Literatures (Medical) associated with Siponimod Fumaric Acid

01 Dec 2025·Lancet Regional Health-Europe

The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis

Article

Author: Cagol, Alessandro ; Schaedelin, Sabine ; Sormani, Maria Pia ; Pretzsch, Roxanne ; Granziera, Cristina ; Kappos, Ludwig

Background:

Multiple treatments have demonstrated efficacy in preventing brain volume loss (BVL) in randomized controlled trials (RCTs) for multiple sclerosis (MS). However, assessing their relative effectiveness remains challenging due to limited head-to-head comparisons. Additionally, the relationship between treatment effects on BVL and disability accumulation is not established for newer therapies. This study aimed to compare the efficacy of approved disease-modifying therapies (DMTs) in reducing BVL in MS and to investigate the association between treatment effects on BVL and disability accumulation.

Methods:

In this systematic review and network meta-analysis, we included all RCTs enrolling adults with MS that evaluated FDA-approved DMTs and reported BVL outcomes over at least one year. We searched PubMed, Embase, and Cochrane from inception to September 2024. Following PRISMA guidelines, two reviewers independently extracted data on BVL, MRI lesion activity, and disability progression. We conducted a mixed-effects network meta-analysis with placebo as the reference group. Meta-regression analyses examined the association between treatment effects on BVL and disability progression, adjusting for MRI lesion activity.The primary outcome was BVL. Secondary outcomes included MRI lesion accumulation and risk of confirmed disability progression. Effect sizes were reported as the ratio of means (ROM) and hazard ratios (HRs), with 95% confidence intervals (CIs). This study is registered with PROSPERO (CRD420251034936).

Findings:

We included 33 RCTs evaluating 16 DMTs and 26,247 patients. Eight DMTs significantly reduced BVL compared to placebo, including ponesimod (ROM = 0.52; 95%-CI: 0.35-0.77), ofatumumab (ROM = 0.58; 95%-CI: 0.40-0.83), alemtuzumab (ROM = 0.63; 95%-CI: 0.49-0.83), teriflunomide (ROM = 0.71; 95%-CI: 0.52-0.97), ozanimod (ROM = 0.74; 95%-CI: 0.56-0.98), natalizumab (ROM = 0.77; 95%-CI: 0.61-0.96), siponimod (ROM = 0.77; 95%-CI: 0.60-0.98), and fingolimod (ROM = 0.83; 95%-CI: 0.71-0.96). The treatment effect on BVL was associated with the treatment effect on disability accumulation (β = 0.466; p = 0.008), and this association remained significant independently of the treatment effect on MRI activity (β = 0.422; p = 0.005).

Interpretation:

Several DMTs-including newer therapies-significantly reduce BVL, and this effect correlates with reduced disability accumulation. These findings support BVL as a meaningful treatment target in MS.

Funding:

None.

01 Nov 2025·Multiple Sclerosis and Related Disorders

Disease modifying therapy after autologous haematopoietic stem cell transplantation in multiple sclerosis patients: 10-years follow-up data from Lithuania

Article

Author: Pečeliūnas, Valdas ; Žučenka, Andrius ; Griškevičius, Laimonas ; Giedraitienė, Nataša ; Kizlaitienė, Rasa ; Dementavičienė, Jūratė ; Kaubrys, Gintaras

BACKGROUND:

There is limited information reported on the management of disease modifying treatment (DMT) in patients with multiple sclerosis (MS) who have been treated with autologous hematopoietic stem cell transplantation (AHSCT).

METHODS:

We conducted a single-centre prospective study of patients with highly active relapsing-remitting MS who underwent AHSCT in Lithuania from May 2014 till January 2025.

RESULTS:

Forty-two patients were selected and treated with AHSCT. 65.0 % of patients who underwent AHSCT achieved No Evidence of Disease Activity-3 (NEDA-3) over a 65-month median follow-up period. 35.6 % of patients experienced improvement in their Expanded Disability Status Scale (EDSS) scores by the third month post-transplant, and this improvement was maintained throughout the follow-up period. Twelve patients (28.5 %) who experienced disease activity after AHSCT were treated with DMT: eight patients (19.0 %) were treated with ocrelizumab, and in four patients (9.5 %), SPMS was diagnosed and patients were treated with siponimod. Five patients who were treated with ocrelizumab after AHSCT achieved NEDA-3, three of whom had been on DMT for >12 months.

CONCLUSION:

The majority of patients maintained NEDA-3 up to five years after AHSCT. Patients who did not achieve NEDA-3 were successfully treated with high-efficacy DMT. No mortality was observed in our cohort. These findings support the efficacy and safety of AHSCT, as well as the use of DMT following AHSCT, in patients with highly active relapsing-remitting MS.

01 Oct 2025·Drug Metabolism and Pharmacokinetics

Japanese medicinal drug labeling for use in the clinical setting as informed by pharmacogenomic data on cytochrome P450 enzymes obtained from in silico studies

Review

Author: Yamazaki, Hiroshi ; Shimizu, Makiko ; Tanaka, Yoichi ; Saito, Yoshiro

Although the United States Food and Drug Administration has disclosed a list of drugs with pharmacogenomic biomarkers for drug labeling, there is limited information regarding pharmacogenomic-associated drugs in Japan. Such associations include genetic variants of uridine diphosphate glucuronosyltransferase 1A1 for irinotecan, nudix hydrolase 15 for thiopurine drugs, and cytochrome P450 (P450) 2C9 for siponimod. The effects of such genetic variants on drug concentrations are similar to those from drug interactions. Because of race and dosage differences, the relevance of pharmacogenomic associations in Asian populations requires confirmation. This white paper proposes that in vitro pharmacogenomic information can be used to predict human pharmacokinetics and to describe in drug labels the changes in blood concentrations by genetic variants. For P450 variants CYP2C9∗3, CYP2C19∗2, CYP2C19∗3, CYP2D6∗10, and CYP3A4∗16, we propose using the enzymatic activity parameters obtained from in vitro functional analysis of the drug-metabolizing enzymes for multiple substrate drugs to predict the effects of these variants on human pharmacokinetics. Consequently, in patients prescribed only a single drug, anything more than a "moderate effect" on plasma exposure should be mentioned as a caution in the drug labels; such effects are likely caused by enzyme polymorphisms resulting in similar effects to drug-drug interactions.

30

News (Medical) associated with Siponimod Fumaric Acid

26 Oct 2025

·www.fiercebiotech.com

Novartis goes big for neuroscience with $12B deal for late-stage dystrophy biotech Avidity

Novartis is paying $72 per share of Avidity Biosciences—a 42% increase to Avidity’s $49.15 price at close of trading Friday.\n Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far.The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody-oligonucleotide conjugates. Novartis is justifying the hefty price tag by claiming the deal will “unlock multi-billion-dollar opportunities with planned product launches before 2030.”Those hoped-for launches include delpacibart zotadirsen (del-zota), for which phase 1/2 data in Duchenne muscular dystrophy (DMD) impressed investors last year. The candidate, which uses an anti-TfR1 antibody to deliver an oligonucleotide to target cells, was tied to a statistically significant 25% increase in dystrophin production among people amenable to exon 44 skipping.The rest of the late-stage RNA therapy pipeline is made up of delpacibart etedesiran (del-desiran), which is designed to reduce levels of DMPK in people living with myotonic dystrophy type 1 (DM1), and delpacibart braxlosiran (del-brax) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).Novartis is paying $72 per share of Avidity—a 42% increase to Avidity’s $49.15 price at close of trading Friday. This values the company at about $12 billion on a fully diluted basis, Novartis explained in a Oct. 26 release, equating to an enterprise value of about $11 billion at the deal’s expected closure in the first half of 2026.That eleven-figure price tag makes the Avidity acquisition the second biggest pharma deal of the year—only surpassed by Johnson & Johnson’s $14.6 billion buyout of central-nervous-system-focused Intra-Cellular Therapies back in January.Despite all the cash on the table, not all of Avidity’s pipeline is coming over to Novartis. The biotech’s early-stage precision cardiology programs, which include candidates for rare genetic cardiomyopathies, will be spun out into a new company. This new entity will also retain responsibility for Avidity’s cardio-focused collaborations with Bristol Myers Squibb and Eli Lilly.Novartis is already an established player in the neuroscience space, thanks to multiple sclerosis drugs Kesimpta, Mayzent and Gilenya.The pharma’s focus on Avidity’s neuroscience capabilities, which include a new way of delivering RNA medicines to muscle, makes sense in the context of the pharma’s wider M&A strategy. Back in November 2024, Novartis penned a $1.1 billion deal for Kate Therapeutics, which also had preclinical gene therapy programs aimed at DMD, DM1 and FSHD.In Sunday’s release, Novartis CEO Vas Narasimhan said Avidity’s “pioneering AOC platform for RNA therapeutics and its late-stage assets” would “bolster our commitment to delivering innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”“The Avidity team has built robust programs with industry-leading delivery of RNA therapeutics to muscle tissue,” Narasimhan added. “We look forward to developing these programs to meaningfully change the trajectory of diseases for patients.” Many Big Pharmas have struggled with muscular dystrophy candidates, including Roche and its Sarepta Therapeutics-partnered Elevidys, which has been on a regulatory roller coaster this year related to reports of two deaths among patients who had received the gene therapy.Avidity suffered its own setbacks in the past, notably a partial clinical hold placed on its DM1 therapy back in 2022 after a serious adverse event was reported in one patient. More recently, concerns from analysts about the safety data for del-zota appeared to have been assuaged by some fresh findings in March.Avidity CEO Sarah Boyce said in yesterday’s release that the company has “expanded the possibilities of what RNA therapeutics can deliver to patients by advancing innovative science and creating an organization with a strong commitment to providing access to our potential medicines.”“We are confident that this transaction with Novartis maximizes value for our investors and will support the global expansion of our neuroscience pipeline,” Boyce added.

AcquisitionOligonucleotide

02 Sep 2025

·www.biospace.com

Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program

iStock, Veronika Oliinyk Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease. Arrowhead Pharmaceuticals has notched another major partnership with billion-dollar potential. Novartis has signed on to develop the RNA interference specialist’s preclinical Parkinson’s disease program for $200 million upfront. On the back end, Arrowhead could be eligible for up to $2 billion in milestones, plus royalties on future sales, according to a Tuesday morning press release . The deal adds to the list of heavyweight partners Arrowhead has collected, which already included Amgen, GSK and Takeda. Its biggest partnership, though, is with Sarepta Therapeutics ; the November 2024 deal is worth upwards of $11 billion if all the programs are a success. Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, or neurodegenerative disorders such as Parkinson’s, that are caused by the buildup of the protein alpha-synuclein in the brain. The deal also includes other targets using Arrowhead’s Targeted RNAi Molecule, or TRiM, platform that have yet to be named, according to the release. Arrowhead will continue with preclinical work for the programs up to a clinical trial application, when Novartis will take over. Besides the partnered programs, Arrowhead has a wholly owned pipeline that includes lead asset plozasiran. The drug is currently awaiting a November decision from the FDA to treat familial chylomicronemia syndrome (FCS), a rare genetic metabolic disorder that prevents the body from breaking down fats. The company is also working on two obesity assets, including ARO-ALK7, which is meant to silence the  ACVR1C  gene, in turn reducing the risk of obesity-related metabolic complications.  CEO Chris Anzalone told BioSpace last month that he aspires to build Arrowhead into a company like Vertex or Regeneron by building long-term value as an independent entity. Novartis’ neurodegenerative pipeline is stacked with assets in multiple sclerosis, myasthenia gravis and Huntington’s disease. The program is anchored by approved therapies Mayzent and Fabhalta. This is not Novartis’ first foray into siRNA therapies, however. The Swiss pharma has Leqvio, which is approved for lowering lipoprotein cholesterol. The drug was licensed from Alnylam, Arrowhead’s more-senior peer in the RNAi world, in January 2020.

Drug ApprovalLicense out/inOligonucleotide

01 May 2025

·www.biospace.com

Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint

iStock, dickcraft According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug development in multiple sclerosis. Immunic’s oral multiple sclerosis drug failed to significantly slow the loss of brain volume in patients with a progressing form of the neurodegenerative disorder during a Phase II clinical trial. But according to CEO Daniel Vitt, it’s no big deal. “Nobody should care at all about whole brain volume change anymore,” Vitt said during an investor call on Wednesday to discuss the mid-stage data, noting that having brain volume as a primary endpoint of the Phase II study was just a “leftover” of a trial design that the biotech settled on “five years ago.” Instead, the field has now focused on using disability as an endpoint, Vitt said, noting that Immunic is taking the same approach, particularly for its Phase III trial. In that regard, Vitt asserted that Wednesday’s readout was a “very, very clear positive outcome.” Leerink analysts said the same thing, calling the CALLIPER results for the therapy, a Nurr1 activator called vidofludimus calcium, “positive” and “competitive” in an investor note on Wednesday. Vidofludimus calcium, according to the analysts, “demonstrated a competitive risk/benefit profile” in primary progressive multiple sclerosis (MS), as compared with Roche’s Ocrevus, and in non-active secondary progressive MS, relative to Novartis’ Mayzent and Sanofi’s tolebrutinib. Of course, this analysis comes with “usual cross-trial comparison caveats,” Leerink cautioned. “We believe the molecule has now demonstrated disease-modifying activity in a difficult-to-treat patient population with limited active lesions,” the analysts added. Immunic is running the Phase III ENSURE program to assess vidofludimus calcium, with data expected next year, Vitt said on the call. Leerink is likewise bullish about Immunic’s prospects here, with its analysts expecting a 50% probability of success. Data from CALLIPER showed that vidofludimus calcium improved the annualized rate of brain volume change by 5% relative to placebo—an effect that failed to reach statistical significance. Immunic, however, chose to focus on the clinical outcomes. The likelihood of having disability worsening events at 24 weeks, for instance, was 20% lower in the vidofludimus calcium group, as compared with placebo. This effect remained consistent or increased even further in various patient subgroups, including in those with primary progressive MS and in those without inflammatory lesions at baseline. As for safety, there were no new signals of concern with vidofludimus calcium. Severe side effects were “rare,” according to Immunic, and occurred at similar frequencies between the treatment arms: 8.1% in patients on vidofludimus calcium and 6.5% of placebo counterparts.

Phase 2Clinical ResultPhase 3

100 Deals associated with Siponimod Fumaric Acid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Siponimod Fumaric Acid	L04AA42	DB12371

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis, Secondary Progressive	European Union	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis, Secondary Progressive	Iceland	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis, Secondary Progressive	Liechtenstein	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis, Secondary Progressive	Norway	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis	United States	Novartis Pharmaceuticals Corp.	26 Mar 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple sclerosis relapse	Phase 3	United States	Novartis Pharmaceuticals Corp.	14 Feb 2019
Multiple sclerosis relapse	Phase 3	Puerto Rico	Novartis Pharmaceuticals Corp.	14 Feb 2019
Rhabdomyosarcoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	14 Feb 2019
Rhabdomyosarcoma	Phase 3	Puerto Rico	Novartis Pharmaceuticals Corp.	14 Feb 2019
Alzheimer Disease	Phase 2	United States	Novartis AG	01 Jul 2025
Alzheimer Disease	Phase 2	United States	Laboratory Corporation of America Holdings	01 Jul 2025
Mild cognitive disorder	Phase 2	United States	Novartis AG	01 Jul 2025
Mild cognitive disorder	Phase 2	United States	Laboratory Corporation of America Holdings	01 Jul 2025
Cerebral Hemorrhage	Phase 2	United States	Novartis Pharmaceuticals Corp.	24 Dec 2017
Hemorrhagic stroke	Phase 2	United States	Novartis Pharmaceuticals Corp.	24 Dec 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04925557 (CTgov)	Phase 2/3	Multiple Sclerosis, Secondary Progressive	8	Ocrevus (Ocrevus)	fdyueqgslq(yhkfcclral) = tbeyzkebfc orfbmwgtsy (lkexsojotf, dagrljedix - ginatfsurx) View more	-	13 May 2025
				Mayzent (Mayzent)	fdyueqgslq(yhkfcclral) = zxyutxvjpc orfbmwgtsy (lkexsojotf, yzwzkqcucw - zjgwbzpgkf) View more
NCT03623243 (EXCHANGE, Pubmed \| Mult Scler)	Phase 3	Multiple sclerosis relapse	185	Siponimod	pxqydukdav(lzgvzxwzvq) = 3.8% (n = 7) ezmpktxosq (fysasytzzw ) View more	Positive	18 Apr 2025
ECTRIMS2023	Not Applicable	Multiple Sclerosis	67	Siponimod	lbprhxvbfe(ymqmcvellp) = oaenfdpjhw pacrpfmxpr (vxluldkshk )	-	01 Oct 2023
ACTRIMS2023	Not Applicable	Multiple Sclerosis, Secondary Progressive Second line	29	Siponimod	ozbfrvvjcn(violctgelr) = 4 patients discontinued treatment due to adverse events and one by personal decision. 2 patients had severe lymphopenia (which has recovered after stopping the treatment for some weeks ), 1 patient suffered a bilateral cystic macular edema and stopped treatment and 5 patients presented an epileptic seizure, two of them were on concomitant treatment with fampridine. Three of them have discontinued the treatment. No alterations in liver enzymes have been observed. No documented increase in frequent infections. wupthvsjrv (lwypkhyubh ) View more	Positive	30 May 2023
EXPAND (ECTRIMS2022)	Phase 3	Multiple Sclerosis	1,651	Siponimod	eslvogrgpx(eiciqxxufz) = only 29% of 243 possible EQ-5D health profiles were observed. Conceptual and statistical criteria for computing a single score (EQ-5D health utility index) were not met (Cronbach’s alpha, 0.61; first principal component explained 40%; person separation index, 0.56). EQ-5D item-scored health status correlated only 0.40 with EQ-5D thermometer-scored health status (16% shared variance). EQ-5D item scores remained unchanged in up to 93.5% of patients, when there was change in other related PROs. Results question EQ-5D’s validity and responsiveness mgxqttnota (lekhgqldsy ) View more	-	26 Oct 2022
				Placebo
ECTRIMS2022	Not Applicable	Multiple Sclerosis, Secondary Progressive CYP2C9 genotype	-	Siponimod 2mg	kvnnxbcxqt(qguylfxsmy) = A total of 90 patients discontinued the study; 48 prior to and 42 after siponimod exposure wvrqyqfymo (shfgoobndo )	-	12 Oct 2022
				Siponimod 1mg
ECTRIMS2022	Not Applicable	COVID-19	-	Fingolimod	aqaiepptqe(rlscvmrmpx) = dbgjbdwzbj sjrwtvqbga (ttyajqzplx ) View more	-	12 Oct 2022
				Siponimod	aqaiepptqe(rlscvmrmpx) = ldqhgjxgdm sjrwtvqbga (ttyajqzplx ) View more
NCT01665144 (EXPAND, Pubmed)	Phase 3	Multiple Sclerosis, Secondary Progressive	779	Siponimod	vwenoxnlwz(jlgkfuyaaj) = jvhenmsngr ojaiveqidk (bgawsdcxav )	Positive	31 May 2022
				Placebo	vwenoxnlwz(jlgkfuyaaj) = gksofdyafr ojaiveqidk (bgawsdcxav )
NCT01665144 \| NCT00731692 (Pubmed \| Neurology)	Phase 3	Multiple Sclerosis, Chronic Progressive plasma neurofilament light	-	Siponimod	qrpocgrvlw(ukeyzyoqgd) = hwuwznlsiv svblwyvryj (osqfznupmw ) View more	Positive	24 May 2022
				Fingolimod	-
NCT01665144 (EXPAND, AAN2022)	Phase 3	Multiple Sclerosis, Secondary Progressive	779	Siponimod 2 mg daily	iexnyrmjpk(ghjgwvhjhu): HR = 0.7 (95% CI, 0.49 - 0.98), P-Value = 0.0383 View more	Positive	03 May 2022
				Placebo